{"id":37963,"date":"2022-06-28T11:48:08","date_gmt":"2022-06-28T11:48:08","guid":{"rendered":"https:\/\/www.elza-institute.com\/?p=37963"},"modified":"2024-07-15T09:21:24","modified_gmt":"2024-07-15T09:21:24","slug":"keratoconus-and-down-syndrome-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.elza-institute.com\/pt\/keratoconus-and-down-syndrome-clinical-trial\/","title":{"rendered":"Queratocone e S\u00edndrome de Down"},"content":{"rendered":"<p>As pessoas com S\u00edndrome de Down t\u00eam um risco desproporcionalmente mais elevado de desenvolver ceratocone do que a popula\u00e7\u00e3o em geral, e muitas delas s\u00e3o submetidas a cross-linking corneano (CXL) para impedir a progress\u00e3o do ceratocone. Apesar disso, \u00e0 exce\u00e7\u00e3o de alguns relatos de casos, n\u00e3o foram publicados at\u00e9 \u00e0 data estudos sobre a efic\u00e1cia do CXL em doentes com ceratocone e S\u00edndrome de Down.<\/p>\n<p>Prof. <a href=\"https:\/\/www.elza-institute.com\/pt\/sobre\/farhad-hafezi\/\">Farhad Hafezi,<\/a> Diretor M\u00e9dico do Instituto ELZA, fez parte de um grupo de estudo internacional que realizou um <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35686709\/\">ensaio cl\u00ednico aleat\u00f3rio<\/a> O estudo de caso da CXL, realizado por um grupo de investigadores, comparou dois protocolos de CXL em 27 pessoas com idades compreendidas entre os 10 e os 20 anos, com s\u00edndrome de Down e ceratocone progressivo em ambos os olhos. Compararam a efic\u00e1cia do CXL padr\u00e3o do \"protocolo de Dresden\" (DP) com um protocolo de CXL acelerado (A-CXL). Foi selecionado aleatoriamente um protocolo para o olho direito do doente e o olho esquerdo do doente recebeu o outro protocolo. Ambos os protocolos envolveram a remo\u00e7\u00e3o do epit\u00e9lio da c\u00f3rnea e a satura\u00e7\u00e3o da camada estrutural da c\u00f3rnea abaixo, o estroma, com riboflavina. A riboflavina \u00e9 activada pela luz UV, que estabelece liga\u00e7\u00f5es cruzadas entre as mol\u00e9culas do estroma, o que resulta numa c\u00f3rnea mais forte, que dever\u00e1 impedir a progress\u00e3o do ceratocone. As diferen\u00e7as entre os protocolos residem no facto de o bra\u00e7o DP-CXL ter recebido a tradicional irradia\u00e7\u00e3o de luz ultravioleta (UV) de 3 mW\/cm\u00b2 durante 30 minutos, para fornecer uma dose total de UV (flu\u00eancia) de 5,4 J\/cm\u00b2, ao passo que o bra\u00e7o A-CXL recebeu uma intensidade de UV tr\u00eas vezes superior (9 mW\/cm\u00b2), fornecida durante um per\u00edodo tr\u00eas vezes mais curto (10 minutos).<\/p>\n<p>Tr\u00eas anos ap\u00f3s os procedimentos, o que \u00e9 que os investigadores descobriram? O A-CXL e o DP-CXL resultaram num efeito de aplana\u00e7\u00e3o semelhante, mas o DP-CXL foi mais capaz de manter a rigidez da c\u00f3rnea em c\u00f3rneas mais fracas. Apesar de a A-CXL ter apresentado resultados est\u00e1veis durante 2 anos, registou-se uma diminui\u00e7\u00e3o da rigidez da c\u00f3rnea no terceiro ano, o que significa que vale a pena acompanhar estes doentes durante um per\u00edodo ainda mais longo.<\/p>\n<p>Ler o documento <a href=\"https:\/\/journals.healio.com\/doi\/abs\/10.3928\/1081597X-20220329-01\">aqui<\/a>.<\/p>\n<p><a href=\"https:\/\/journals.healio.com\/doi\/abs\/10.3928\/1081597X-20220329-01\"><img fetchpriority=\"high\" decoding=\"async\" class=\"size-medium wp-image-37966 aligncenter\" src=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-cover-217x300.png\" alt=\"Ensaio cl\u00ednico CXL em ceratocone e S\u00edndrome de Down\" width=\"217\" height=\"300\" srcset=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-cover-217x300.png 217w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-cover-9x12.png 9w, https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-cover.png 482w\" sizes=\"(max-width: 217px) 100vw, 217px\" \/><\/a><\/p>\n<p><strong>Refer\u00eancia<\/strong><\/p>\n<p>Hashemi H, Roberts CJ, Ambr\u00f3sio R, et al. Ensaio cl\u00ednico comparativo contralateral randomizado de CXL padr\u00e3o (3 mW\/cm\u00b2) versus acelerado (9 mW\/cm\u00b2) em pacientes com s\u00edndrome de down: resultados de 3 anos. J Refract Surg. 2022;38(6):381-388.<\/p>","protected":false},"excerpt":{"rendered":"<p>People with Down Syndrome have a disproportionately higher risk of developing keratoconus than the general population, and many go on to receive corneal cross-linking (CXL) to stop keratoconus from progressing. Despite this, except for a few case reports, no studies have been published to date on the effectiveness of CXL in patients with keratoconus and [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":37968,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[214,1,95],"tags":[506,101,452,125,130,172,564,565,133],"class_list":["post-37963","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farhad-hafezi","category-general-news","category-scientific-article","tag-accelerated","tag-children","tag-clinical-trial","tag-cornea","tag-cross-linking","tag-down-syndrome","tag-downs-syndrome","tag-ds","tag-epi-off"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Keratoconus and Down Syndrome - The ELZA Institute<\/title>\n<meta name=\"description\" content=\"Keratoconus and Down Syndrome: How effective is CXL at treating KC in Down Syndrome? This is the first clinical trial to answer the question.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.elza-institute.com\/pt\/keratoconus-and-down-syndrome-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keratoconus and Down Syndrome - The ELZA Institute\" \/>\n<meta property=\"og:description\" content=\"Keratoconus and Down Syndrome: How effective is CXL at treating KC in Down Syndrome? This is the first clinical trial to answer the question.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.elza-institute.com\/pt\/keratoconus-and-down-syndrome-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"The ELZA Institute\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ELZA.Institute\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-28T11:48:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-15T09:21:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Mark Hillen\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark Hillen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/\"},\"author\":{\"name\":\"Mark Hillen\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\"},\"headline\":\"Keratoconus and Down Syndrome\",\"datePublished\":\"2022-06-28T11:48:08+00:00\",\"dateModified\":\"2024-07-15T09:21:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/\"},\"wordCount\":341,\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg\",\"keywords\":[\"accelerated\",\"Children\",\"clinical trial\",\"Cornea\",\"Cross-Linking\",\"Down Syndrome\",\"Downs Syndrome\",\"DS\",\"epi-off\"],\"articleSection\":[\"Farhad Hafezi\",\"News\",\"Scientific article\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/\",\"url\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/\",\"name\":\"Keratoconus and Down Syndrome - The ELZA Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.elza-institute.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg\",\"datePublished\":\"2022-06-28T11:48:08+00:00\",\"dateModified\":\"2024-07-15T09:21:24+00:00\",\"description\":\"Keratoconus and Down Syndrome: How effective is CXL at treating KC in Down Syndrome? This is the first clinical trial to answer the question.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg\",\"width\":1200,\"height\":600,\"caption\":\"Keratoconus and Down Syndeomw - CXL clinical trial paper cover art\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.elza-institute.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Farhad Hafezi\",\"item\":\"https:\/\/www.elza-institute.com\/farhad-hafezi\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Keratoconus and Down Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.elza-institute.com\/#website\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"name\":\"The ELZA Institute\",\"description\":\"Swiss EyeCare at its finest\",\"publisher\":{\"@id\":\"https:\/\/www.elza-institute.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.elza-institute.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.elza-institute.com\/#organization\",\"name\":\"The ELZA Institute\",\"url\":\"https:\/\/www.elza-institute.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"contentUrl\":\"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg\",\"width\":1181,\"height\":453,\"caption\":\"The ELZA Institute\"},\"image\":{\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ELZA.Institute\/\",\"https:\/\/x.com\/ELZA_Institute\",\"https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15\",\"name\":\"Mark Hillen\",\"url\":\"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ceratocone e s\u00edndrome de Down - O Instituto ELZA","description":"Queratocone e S\u00edndroma de Down: Qual a efic\u00e1cia do CXL no tratamento do Queratocone na S\u00edndrome de Down? Este \u00e9 o primeiro ensaio cl\u00ednico a responder a esta quest\u00e3o.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.elza-institute.com\/pt\/keratoconus-and-down-syndrome-clinical-trial\/","og_locale":"pt_PT","og_type":"article","og_title":"Keratoconus and Down Syndrome - The ELZA Institute","og_description":"Keratoconus and Down Syndrome: How effective is CXL at treating KC in Down Syndrome? This is the first clinical trial to answer the question.","og_url":"https:\/\/www.elza-institute.com\/pt\/keratoconus-and-down-syndrome-clinical-trial\/","og_site_name":"The ELZA Institute","article_publisher":"https:\/\/www.facebook.com\/ELZA.Institute\/","article_published_time":"2022-06-28T11:48:08+00:00","article_modified_time":"2024-07-15T09:21:24+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg","type":"image\/jpeg"}],"author":"Mark Hillen","twitter_misc":{"Escrito por":"Mark Hillen","Tempo estimado de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/"},"author":{"name":"Mark Hillen","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15"},"headline":"Keratoconus and Down Syndrome","datePublished":"2022-06-28T11:48:08+00:00","dateModified":"2024-07-15T09:21:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/"},"wordCount":341,"publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"image":{"@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg","keywords":["accelerated","Children","clinical trial","Cornea","Cross-Linking","Down Syndrome","Downs Syndrome","DS","epi-off"],"articleSection":["Farhad Hafezi","News","Scientific article"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/","url":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/","name":"Ceratocone e s\u00edndrome de Down - O Instituto ELZA","isPartOf":{"@id":"https:\/\/www.elza-institute.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg","datePublished":"2022-06-28T11:48:08+00:00","dateModified":"2024-07-15T09:21:24+00:00","description":"Queratocone e S\u00edndroma de Down: Qual a efic\u00e1cia do CXL no tratamento do Queratocone na S\u00edndrome de Down? Este \u00e9 o primeiro ensaio cl\u00ednico a responder a esta quest\u00e3o.","breadcrumb":{"@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#primaryimage","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2022\/06\/Hashemi-paper-featured-image.jpg","width":1200,"height":600,"caption":"Keratoconus and Down Syndeomw - CXL clinical trial paper cover art"},{"@type":"BreadcrumbList","@id":"https:\/\/www.elza-institute.com\/keratoconus-and-down-syndrome-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.elza-institute.com\/"},{"@type":"ListItem","position":2,"name":"Farhad Hafezi","item":"https:\/\/www.elza-institute.com\/farhad-hafezi\/"},{"@type":"ListItem","position":3,"name":"Keratoconus and Down Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.elza-institute.com\/#website","url":"https:\/\/www.elza-institute.com\/","name":"O Instituto ELZA","description":"Swiss EyeCare no seu melhor","publisher":{"@id":"https:\/\/www.elza-institute.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.elza-institute.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/www.elza-institute.com\/#organization","name":"O Instituto ELZA","url":"https:\/\/www.elza-institute.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","contentUrl":"https:\/\/www.elza-institute.com\/wp-content\/uploads\/2016\/04\/ELZA-logo-V4.jpg","width":1181,"height":453,"caption":"The ELZA Institute"},"image":{"@id":"https:\/\/www.elza-institute.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ELZA.Institute\/","https:\/\/x.com\/ELZA_Institute","https:\/\/www.linkedin.com\/company\/elza-institute?trk=top_nav_home"]},{"@type":"Person","@id":"https:\/\/www.elza-institute.com\/#\/schema\/person\/e3929262886a5a60dd6965a6bc721d15","name":"Mark Hillen","url":"https:\/\/www.elza-institute.com\/pt\/author\/markhillen\/"}]}},"_links":{"self":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/37963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/comments?post=37963"}],"version-history":[{"count":0,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/posts\/37963\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media\/37968"}],"wp:attachment":[{"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/media?parent=37963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/categories?post=37963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.elza-institute.com\/pt\/wp-json\/wp\/v2\/tags?post=37963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}